Drug Trial Radar · NCT05664152
An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years
Last checked: Nov 19, 2026Latest source record: Dec 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
250
Planned (sponsor's estimate)
Start
Feb 2023
Primary completion
Apr 2023
Study completion Jun 2023
Sponsor
- Lead sponsor
- GC Biopharma CorpIndustry
- Sponsor type
- Industry
- First posted
- Dec 23, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 months, up to 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are: * Safety of BARYCELA inj. (Live attenuated varicella vaccine for injection) * Immunogenicity of BARYCELA inj. (Live attenuated varicella vaccine for injection) Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).
Conditions
- Varicella Zoster Virus Infection
Interventions
MG1111Biological
BARYCELA inj.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of BARYCELA inj.: Solicited local and systemic reactogenicityTime frame: within 30-minute post vaccination
- Safety of BARYCELA inj.: The incidence and severity of solicited local and systemic AEsTime frame: during 7 days post vaccination
- Safety of BARYCELA inj.: Incidence and severity of unsolicited AEsTime frame: during 42 days post vaccination
- Safety of BARYCELA inj.: Incidence of adverse event of special interestTime frame: during 42 days post vaccination
- Safety of BARYCELA inj.: Vital signsTime frame: Day0(Pre vaccination), 42 days post vaccination
- Safety of BARYCELA inj.: Body temperatureTime frame: Day0(Pre vaccination), 42 days post vaccination
- Safety of BARYCELA inj.: Complete physical examinationTime frame: Day0(Pre vaccination), 42 days post vaccination
- Safety of BARYCELA inj.: Symptom-directed physical examinationTime frame: Day0(Pre vaccination), during 42 days post vaccination
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.